Health Trials

About this trial

The purpose of this trial is to identify a safe maximum tolerated dose level for MRI-guided Stereotactic Body Radiation Therapy (SBRT) treatment of bowel and liver metastases, respectively.

Eligible participants will be on study for up to 12 months.

Eligibility criteria

Qualifiers

Have a diagnosis of histologically confirmed or clinically suspected metastatic cancer to the liver.

Participant must be a candidate for SBRT to at least one intrahepatic lesion but no more than 6 intrahepatic lesions.

Participant must be a candidate for treatment on the ViewRay treatment unit. Must be screened to rule out implants and devices that are not MRI compatible.

Be willing and able to provide written informed consent.

Disqualifiers

Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the initiation of SBRT.

History of a second invasive cancer in the last 3 years (except for appropriately treated low-risk prostate cancer, treated non-melanoma skin cancer, appropriately treated ductal carcinoma in situ or early stage invasive carcinoma of breast appropriately treated in situ/early stage cervical/endometrial cancer.

Has an active infection requiring systemic therapy.

Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

Trial design

Treatments tested in this trial

  • SBRT

Treatment groups

32 Participants
are divided into 1 treatment group

Locations

1
University of Wisconsin53792, MadisonWisconsin, United States

Sponsors and collaborators

University of Wisconsin, Madison

Lead sponsor

Source ClinicalTrials.gov